TY - JOUR A1 - Schraplau, Anne A1 - Schewe, Bettina A1 - Neuschäfer-Rube, Frank A1 - Ringel, Sebastian A1 - Neuber, Corinna A1 - Kleuser, Burkhard A1 - Püschel, Gerhard Paul T1 - Enhanced thyroid hormone breakdown in hepatocytes by mutual induction of the constitutive androstane receptor (CAR, NR1I3) and arylhydrocarbon receptor by benzo[a]pyrene and phenobarbital JF - Toxicology N2 - Xenobiotics may interfere with the hypothalamic-pituitary-thyroid endocrine axis by inducing enzymes that inactivate thyroid hormones and thereby reduce the metabolic rate. This induction results from an activation of xeno-sensing nuclear receptors. The current study shows that benzo[a]pyrene, a frequent contaminant of processed food and activator of the arylhydrocarbon receptor (AhR) activated the promoter and induced the transcription of the nuclear receptor constitutive androstane receptor (CAR, NR1I3) in rat hepatocytes. Likewise, phenobarbital induced the AhR transcription. This mutual induction of the nuclear receptors enhanced the phenobarbital-dependent induction of the prototypic CAR target gene Cyp2b1 as well as the AhR-dependent induction of UDP-glucuronosyltransferases. In both cases, the induction by the combination of both xenobiotics was more than the sum of the induction by either substance alone. By inducing the AhR, phenobarbital enhanced the benzo[a]pyrene-dependent reduction of thyroid hormone half-life and the benzo[a]pyrene-dependent increase in the rate of thyroid hormone glucuronide formation in hepatocyte cultures. CAR ligands might thus augment the endocrine disrupting potential of AhR activators by an induction of the AhR. (C) 2014 Elsevier Ireland Ltd. All rights reserved. KW - Endocrine disruption KW - Xenobesity KW - Aryl-hydrocarbon receptor KW - Cyp2b1 KW - Thyroid hormone KW - UDP-glucuronosyltransferase Y1 - 2015 U6 - https://doi.org/10.1016/j.tox.2014.12.004 SN - 0300-483X VL - 328 SP - 21 EP - 28 PB - Elsevier CY - Clare ER - TY - JOUR A1 - Neuschaefer-Rube, Frank A1 - Schraplau, Anne A1 - Schewe, Bettina A1 - Lieske, Stefanie A1 - Kruetzfeldt, Julia-Mignon A1 - Ringel, Sebastian A1 - Henkela, Janin A1 - Birkenfeld, Andreas L. A1 - Püschel, Gerhard Paul T1 - Arylhydrocarbon receptor-dependent mIndy (SIc13a5) induction as possible contributor to benzo[a]pyrene-induced lipid accumulation in hepatocytes JF - Toxicology N2 - Non-alcoholic fatty liver disease is a growing problem in industrialized and developing countries. Hepatic lipid accumulation is the result of an imbalance between fatty acid uptake, fatty acid de novo synthesis, beta-oxidation and secretion of triglyceride-rich lipoproteins from the hepatocyte. A central regulator of hepatic lipid metabolism is cytosolic citrate that can either be derived from the mitochondrium or be taken up from the blood via the plasma membrane sodium citrate transporter NaCT, the product of the mammalian INDY gene (SLC13A5). mINDY ablation protects against diet-induced steatosis whereas mINDY expression is increased in patients with hepatic steatosis. Diet-induced hepatic steatosis is also enhanced by activation of the arylhyrocarbon receptor (AhR) both in humans and animal models. Therefore, the hypothesis was tested whether the mINDY gene might be a target of the AhR. In accordance with such a hypothesis, the AhR activator benzo[a]pyrene induced the mINDY expression in primary cultures of rat hepatocytes in an AhR-dependent manner. This induction resulted in an increased citrate uptake and citrate incorporation into lipids which probably was further enhanced by the benzo[a]pyrene-dependent induction of key enzymes of fatty acid synthesis. A potential AhR binding site was identified in the mINDY promoter that appears to be conserved in the human promoter. Elimination or mutation of this site largely abolished the activation of the mINDY promoter by benzo[a]pyrene. This study thus identified the mINDY as an AhR target gene. AhR-dependent induction of the mINDY gene might contribute to the development of hepatic steatosis. (C) 2015 Elsevier Ireland Ltd. All rights reserved. KW - SLC13A5 KW - Non-alcoholic fatty liver disease KW - NAFLD Y1 - 2015 U6 - https://doi.org/10.1016/j.tox.2015.08.007 SN - 0300-483X VL - 337 SP - 1 EP - 9 PB - Elsevier CY - Clare ER -